2024
DOI: 10.3390/biomedicines12040898
|View full text |Cite
|
Sign up to set email alerts
|

The Pharmacological Effect of Hemin in Inflammatory-Related Diseases: A Systematic Review

João Estarreja,
Gonçalo Caldeira,
Inês Silva
et al.

Abstract: Background: Hemin is clinically used in acute attacks of porphyria; however, recent evidence has also highlighted its capability to stimulate the heme oxygenase enzyme, being associated with cytoprotective, antioxidant, and anti-inflammatory effects. Indeed, current preclinical evidence emphasizes the potential anti-inflammatory role of hemin through its use in animal models of disease. Nevertheless, there is no consensus about the underlying mechanism(s) and the most optimal therapeutic regimens. Therefore, t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 103 publications
0
1
0
Order By: Relevance
“…Both drugs are approved for treatments in humans, but only sildenafil has been used in neonates for cardiopulmonary problems, such as pulmonary hypertension and broncopulmonary dysplasia ( Dillon et al, 2023 ). Sildenafil was proposed as a potent vasodilator agent ( Kelly et al, 2017 ), while Hemin as an antiremodeling and antioxidant ( Estarreja et al, 2024 ) In this context, there is strong evidence that suggests a potentially beneficial outcome of using these two drugs in treatments to reverse the adverse effects of HAHH exposure. However, to the best of our knowledge, no studies have addressed the effects of hemin and sildenafil on neonatal aortas exposed to chronic hypoxia during the perinatal period.…”
Section: Introductionmentioning
confidence: 99%
“…Both drugs are approved for treatments in humans, but only sildenafil has been used in neonates for cardiopulmonary problems, such as pulmonary hypertension and broncopulmonary dysplasia ( Dillon et al, 2023 ). Sildenafil was proposed as a potent vasodilator agent ( Kelly et al, 2017 ), while Hemin as an antiremodeling and antioxidant ( Estarreja et al, 2024 ) In this context, there is strong evidence that suggests a potentially beneficial outcome of using these two drugs in treatments to reverse the adverse effects of HAHH exposure. However, to the best of our knowledge, no studies have addressed the effects of hemin and sildenafil on neonatal aortas exposed to chronic hypoxia during the perinatal period.…”
Section: Introductionmentioning
confidence: 99%